Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR PUDDING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR PUDDING.
ULTRAVIST 370 vs VARIBAR PUDDING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated non-ionic contrast agent that attenuates X-rays due to its high iodine content (370 mg I/mL), enhancing vascular and tissue contrast during imaging. Does not bind to plasma proteins and has minimal pharmacological effects.
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
Adult: IV administration of 370 mg iodine/mL at 1-1.5 mL/kg (370-555 mg I/kg) for CT; up to 300 mL total. Rate: 1-5 mL/sec.
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to up to 36 hours in severe renal impairment (CrCl <30 mL/min).
Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage.
Renal: 95% unchanged within 24 hours via glomerular filtration; Biliary/Fecal: <5%; negligible biliary excretion.
Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent